2016
DOI: 10.3747/co.23.3108
|View full text |Cite
|
Sign up to set email alerts
|

Progression Pattern and Adverse Events with Bevacizumab in Glioblastoma

Abstract: BackgroundThe use of bevacizumab in the management of glioblastoma multiforme (gbm) remains controversial.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
9
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 21 publications
0
9
0
Order By: Relevance
“…It has become evident in recent years that bevacizumab treatment is not without risk, in particular from wound breakdown and the possibility of inducing a more infiltrative/aggressive tumor after treatment [14]. Our analysis suggests that bevacizumab should be considered more carefully in classical and EGFR-amplified tumors and may be more beneficial for mesenchymal, neural and proneural tumors.…”
Section: Discussionmentioning
confidence: 89%
See 1 more Smart Citation
“…It has become evident in recent years that bevacizumab treatment is not without risk, in particular from wound breakdown and the possibility of inducing a more infiltrative/aggressive tumor after treatment [14]. Our analysis suggests that bevacizumab should be considered more carefully in classical and EGFR-amplified tumors and may be more beneficial for mesenchymal, neural and proneural tumors.…”
Section: Discussionmentioning
confidence: 89%
“…Additional experience with bevacizumab has allowed for clarification of complications of treatment in GBM that include thrombocytopenia, cerebral hemorrhages, arterial thrombo-embolic events, proteinuria, hypertension, visceral perforation, and inhibition of wound healing [812]. Furthermore, as the experience with this therapy grew, a more invasive pattern of progression of GBM has been observed to develop while under anti-angiogenic therapy [13, 14]. A potential mechanism involving the inhibition of the HIF1α mediated hypoxic response in the tumor micro-environment has been proposed to underlie the more invasive or multifocal phenotype [15].…”
Section: Introductionmentioning
confidence: 99%
“…That is, histologic examination of organs such as the brain, heart, liver, and kidney in rodents exposed to high-dose NDAT for weeks has shown no abnormalities (S.A. Mousa, S. Sell, unpublished observations). We would also point out that the use of anti-angiogenic agents in GBM clinical management increases the risk of intratumoral hemorrhage [ 51 , 52 ]. Despite the multifactorial anti-angiogenic properties of Nanotetrac, no hemorrhages occurred in the xenografts of Nanotetrac-treated animals in the present study.…”
Section: Discussionmentioning
confidence: 99%
“…Considering the primary role of the Eph/ephrin system in GBM and the availability of a compound able to specifically target the Eph receptors, we examined whether UniPR1331 was capable of inhibiting GBM growth in vivo . Since anti-angiogenic compounds targeting endothelial cells have been considered for treatment of recurrent GBM [ 17 ] but their clinical benefit was unsatisfactory [ 18 , 19 ], we decided to test the association of UniPR1331 with Bevacizumab, a specific and selective inhibitor of VEGF-VEGFR interaction.…”
Section: Introductionmentioning
confidence: 99%